Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.
暂无分享,去创建一个
D. Ettinger | P. Lorigan | D. Spigel | L. Garbo | M. Renschler | R. Jotte | P. Conkling | J. Oliver | V. Gupta | R. Mcnally